In this sense, we also emphasize the role of anti-Ro/SSA antibodies, review the antibodies shared with other autoimmune diseases and analyze the novel antibodies that could provide valuable information for understanding the pathophysiology of the disease, predicting new clinical profiles in the future and probably helping in the development of new therapeutic targets. This evidence concerns the gene TRIM21 and autoimmune disease.